TY - JOUR
T1 - Use of purified parasite proteins from leishmartia donovani for the rapid serodiagnosis of visceral leishmaniasis
AU - Jaffe, Charles L.
AU - Zalis, Mariano
AU - Jaffe, Charles L.
PY - 1988/6
Y1 - 1988/6
N2 - Serodiagnosis of visceral leishmaniasis (VL) due to Leishmania donovani by using crude parasite antigen is complicated in many endemic areas because of cross-reactions with sera from humans with Chagas’ disease. We used affinity-purified parasite proteins to develop a direct dot-blot assay for VL. Double-blind tests were carried out on sera from 40 patients with well-documented VL, from controls in endemic areas, and from patients with other diseases. Using gp70-2, 36 (90.0%) of 40 sera from patients with kala azar were correctly diagnosed; 1 (1.2%) of 86 sera from patients without kala azar was misdiagnosed. With dp72, 21 (100%) of 21 sera from patients with VL were correctly identified; 5 (7.0%) of 71 negative sera were misdiagnosed. None of the 18 sera from patients with Chagas’ disease reacted positively against gp70-2. Our assay is rapid, simple, and specific and represents a new method for reliably diagnosing and monitoring VL.
AB - Serodiagnosis of visceral leishmaniasis (VL) due to Leishmania donovani by using crude parasite antigen is complicated in many endemic areas because of cross-reactions with sera from humans with Chagas’ disease. We used affinity-purified parasite proteins to develop a direct dot-blot assay for VL. Double-blind tests were carried out on sera from 40 patients with well-documented VL, from controls in endemic areas, and from patients with other diseases. Using gp70-2, 36 (90.0%) of 40 sera from patients with kala azar were correctly diagnosed; 1 (1.2%) of 86 sera from patients without kala azar was misdiagnosed. With dp72, 21 (100%) of 21 sera from patients with VL were correctly identified; 5 (7.0%) of 71 negative sera were misdiagnosed. None of the 18 sera from patients with Chagas’ disease reacted positively against gp70-2. Our assay is rapid, simple, and specific and represents a new method for reliably diagnosing and monitoring VL.
UR - http://www.scopus.com/inward/record.url?scp=0023932406&partnerID=8YFLogxK
U2 - 10.1093/infdis/157.6.1212
DO - 10.1093/infdis/157.6.1212
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 3373022
AN - SCOPUS:0023932406
SN - 0022-1899
VL - 157
SP - 1212
EP - 1220
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -